Table 1.
Clinical and demographic characteristics, outcome, symptoms and treatment of Covid-19 cancer patients
| Characteristics | N | Percentage (%) |
|---|---|---|
| Sex | ||
| Male | 30 | 66.7 |
| Female | 15 | 33.3 |
| Cancer type | ||
| Lung cancer | 17 | 37.8 |
| Breast cancer | 6 | 13.3 |
| Colorectal cancer | 6 | 13.3 |
| Prostate cancer | 5 | 11.1 |
| Other | 11 | 24.5 |
| Cancer staging | ||
| Localized | 6 | 13.3 |
| Locally advanced | 13 | 28.9 |
| Metastatic | 26 | 57.8 |
| Cancer treatment | ||
| No active treatment | 13 | 28.9 |
| Chemotherapy | 19 | 42.2 |
| TKIs | 2 | 4.4 |
| Immunotherapy | 1 | 2.2 |
| New diagnosis | 2 | 4.4 |
| Others | 8 | 17.9 |
| Comorbidities | ||
| Hypertension | 23 | 51.1 |
| Diabetes mellitus | 13 | 28.9 |
| Cardiovascular disease | 4 | 8.8 |
| Chronic kidney disease | 3 | 6.7 |
| COPD | 13 | 28.9 |
| Obesity | 6 | 13.3 |
| Covid-19 diagnosis | ||
| Hospitalization admission | 38 | 84.4 |
| ICU admission | 0 | 0 |
| Home management (discharged from hospital at diagnosis) | 7 | 15.6 |
| Covid-19 outcome | ||
| Dead | 19 | 42.2 |
| Alive | 26 | 57.8 |
| Severe covid-19 infection | 29 | 64.4 |
| Symptoms | ||
| Fever | 38 | 84.4 |
| Cough | 39 | 86.7 |
| Myalgia | 10 | 22.2 |
| Dyspnea | 38 | 84.4 |
| Diarrhea | 1 | 2.2 |
| Covid-19 treatment | ||
| Lopinavir/ritonavir + hydroxychloroquine | 10 | 22.2 |
| Hydroxychloroquine + azithromycin | 18 | 40.0 |
| Lopinavir/ritonavir + hydroxychloroquine + azithromycin | 4 | 8.8 |
| Hydroxichloroquine | 2 | 4.4 |
| Hydroxychloroquine + azithromycin + steroids | 2 | 4.4 |
| Hydroxychloroquine + azithromycin + steroids + tocilizumab | 1 | 2.2 |
TKIs tyrosine kinase inhibitors, COPD chronic obstructive pulmonary disease